- Investing.com
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Medical Tech Frontie | LivaNova leads in cardiopulmonary and neuromodulation, with a $2.28B market cap and potential for growth despite challenges in core markets |
Product Innovation | Essenz heart-lung machine drives growth through 2027, while expanded oxygenator capacity and sleep apnea device show promise for market expansion |
Financial Outlook | Projected 6-7% organic growth and $3.67 EPS for 2025, with analyst price targets ranging from $55 to $61, suggesting potential undervaluation |
Strategic Challenges | Mature markets and legal issues pose risks, but expansion into sleep apnea and depression markets offer new growth avenues for LivaNova |
Metrics to compare | LIVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIVNPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.7x | 21.4x | −0.5x | |
PEG Ratio | 0.02 | 0.04 | 0.00 | |
Price/Book | 2.3x | 3.0x | 2.6x | |
Price / LTM Sales | 1.9x | 4.3x | 3.2x | |
Upside (Analyst Target) | 32.8% | 59.3% | 41.4% | |
Fair Value Upside | Unlock | 7.7% | 6.0% | Unlock |